The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

被引:3
|
作者
Zhang, Lishuo [1 ]
Di, Longjiang [2 ]
Liu, Jinhui [3 ]
Lei, Xianli [4 ]
Gu, Maoli [1 ]
Zhang, Wenjing [3 ]
Wang, Yufu [3 ]
机构
[1] Harbin Med Univ, Dept Urol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[2] Southern Med Univ, Coll Basic Med, Guangzhou, Guangdong, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; long non-coding RNA; cuproptosis; prognosis; immunotherapy; CLASSIFICATION;
D O I
10.3389/fgene.2023.1039813
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cuproptosis is a new form of cell death, the second form of metal ion-induced cell death defined after ferroptosis. Recently, cuproptosis has been suggested to be associated with tumorigenesis. However, the relationship between cuproptosis and patient prognosis in clear cell renal cell carcinoma (ccRCC) in the context of immunotherapy remains unknown. The aim of this study was to investigate the correlation between cuproptosis-related long non-coding RNA (lncRNA) and ccRCC in terms of immunity as well as prognosis. Clinical information on lncRNAs associated with differences in cuproptosis genes in ccRCC and normal tissues was collected from The Cancer Genome Atlas (TCGA) dataset. Univariate Cox regression was used to screen lncRNAs. A total of 11 lncRNAs closely associated with cuproptosis were further screened and established using the least absolute shrinkage and selection operator (LASSO) algorithm and multivariate Cox regression, and the samples were randomly divided into training and test groups. A risk prognostic model was constructed using the training group, and the model was validated using the test group. We investigated the predictive ability of the prognostic risk model in terms of clinical prognosis, tumor mutation, immune escape, immunotherapy, tumor microenvironment, immune infiltration levels, and tumor drug treatment of ccRCC. Using the median risk score, patients were divided into low and high-risk groups. Kaplan-Meier curves showed that the overall survival (OS) of patients in the high-risk group was significantly worse than low-risk group (p < 0.001). Receiver operating characteristic (ROC) curves further validated the reliability of our model. The model consistently and accurately predicted prognosis at 1, 3, and 5 years, with an AUC above 0.7. Tumor cell genes generally precede morphological abnormalities; therefore, the model we constructed can effectively compensate for the traditional method of evaluating the prognosis of patients with renal cancer, and our model was also clinically meaningful in predicting ccRCC staging. In addition, lower model risk scores determined by mutational load indicated a good chance of survival. The high-risk group had greater recruitment of immune cells, while the anti-immune checkpoint immunotherapy was less efficacious overall than that of the low-risk group. Tumor and immune-related pathways were enriched, and anti-tumor agents were selected to improve the survival of ccRCC. This prognostic risk model is based on the levels of cuproptosis-associated lncRNAs and provides a new perspective in the clinical assessment and precise treatment of ccRCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma
    Tian, Xi
    Zhu, Shuxuan
    Liu, Wangrui
    Wu, Xinrui
    Wei, Gaomeng
    Zhang, Ji
    Anwaier, Aihetaimujiang
    Chen, Cong
    Ye, Shiqi
    Che, Xiangxian
    Xu, Wenhao
    Qu, Yuanyuan
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (19) : 17451 - 17466
  • [12] A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma
    Peng, Linjie
    Liang, Jiaming
    Wang, Qi
    Chen, Guodong
    FRONTIERS IN GENETICS, 2022, 13
  • [13] Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
    Xu, Shengxian
    Liu, Dongze
    Chang, Taihao
    Wen, Xiaodong
    Ma, Shenfei
    Sun, Guangyu
    Wang, Longbin
    Chen, Shuaiqi
    Xu, Yong
    Zhang, Hongtuan
    FRONTIERS IN GENETICS, 2022, 13
  • [14] A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma
    Liu, Jia
    Yao, Lin
    Yang, Yong
    Ma, Jinchao
    You, Ruijian
    Yu, Ziyi
    Du, Peng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [15] Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma
    Chen, Yongquan
    Hu, Weijing
    Wei, Xin
    Zhang, Lin
    Shao, Yuan
    Tian, Jinming
    Wang, Dongwen
    Wu, Bo
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2023, 12 (04) : 622 - +
  • [16] A Panel of Four-lncRNA Signature as a Potential Biomarker for Predicting Survival in Clear Cell Renal Cell Carcinoma
    Liu, Haoran
    Ye, Tao
    Yang, Xiaoqi
    Lv, Peng
    Wu, Xiaoliang
    Zhou, Hui
    Zeng, Jin
    Tang, Kun
    Ye, Zhangqun
    JOURNAL OF CANCER, 2020, 11 (14): : 4274 - 4283
  • [17] A Metastasis-Related lncRNA Signature Correlates With the Prognosis in Clear Cell Renal Cell Carcinoma
    Dou, Qian
    Gao, Shun
    Gan, Hua
    Kang, Zhao
    Zhang, Han
    Yang, Yichun
    Tong, Hang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [18] A reactive oxygen species-related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma
    Liu, Hongxiang
    Luo, Yong
    Zhao, Shankun
    Tan, Jing
    Chen, Minjian
    Liu, Xihai
    Ye, Jianheng
    Cai, Shanghua
    Deng, Yulin
    Li, Jinchuang
    He, Huichan
    Zhang, Xin
    Zhong, Weide
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [19] LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma
    Ding, Chenguang
    Han, Feng
    Xiang, Heli
    Xia, Xinxin
    Wang, Yuxiang
    Dou, Meng
    Zheng, Jin
    Li, Yang
    Xue, Wujun
    Ding, Xiaoming
    Tian, Puxun
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (12) : 10406 - 10414
  • [20] Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma
    Hu Wang
    Zhan Yang
    Xingyu He
    Fengran Guo
    Hao Sun
    Sen Xu
    Chao Xu
    Zhu Wang
    Hongzhuang Wen
    Zhihai Teng
    Yaxuan Wang
    Zhenwei Han
    BMC Cancer, 23